CJC-1295
CJC-1295 is an analogue of growth hormone-releasing hormone, also called GHRH. Early human studies found increased growth hormone and insulin-like growth factor 1, or IGF-1, with growth hormone pulsatility preserved.
Research continues to explore CJC-1295 for injury recovery, muscle strength and healthy ageing. Any consideration of use at MRC begins with physician consultation and supervision.
What Is CJC-1295?
CJC-1295 is a synthetic peptide designed to stimulate the pituitary gland. The long-acting form studied in clinical trials contains a drug affinity complex that enables binding to circulating albumin.
Products advertised as CJC-1295 without this complex differ from the long-acting compound, and a physician matches the evidence to the exact formulation.
How Does CJC-1295 Work?
CJC-1295 activates GHRH receptors on pituitary cells, increasing growth hormone secretion and downstream IGF-1 production. This depends on functioning pituitary tissue.
A small human study found preserved growth hormone pulses alongside increased background hormone secretion. Longer studies continue to examine the significance of this secretion pattern for long-term hormone balance.
What Has Research Studied?
Short, placebo-controlled studies in healthy adults assessed hormone concentrations, duration of action and tolerability. They demonstrated sustained hormonal changes rather than established improvements in patient-important recovery outcomes.
Research into CJC-1295 for tendon injuries, body-composition management and age-related symptoms is ongoing, with larger and longer trials underway.
Safety and Medical Supervision
Potential concerns include injection reactions, fluid retention, joint symptoms and altered glucose regulation. Long-term safety and the consequences of sustained IGF-1 elevation remain uncertain.
A physician assesses symptoms, glucose status, pituitary health and medical history before treatment. Product identity, sterility and quality are confirmed as part of the programme.
Frequently Asked Questions
Is CJC-1295 an approved treatment for healthy ageing?
Interest in CJC-1295 for healthy ageing continues to grow, and early trials have shown measurable hormonal changes. A physician can advise whether it suits your goals.
Does CJC-1295 replace growth hormone?
It stimulates the pituitary gland to release growth hormone rather than supplying growth hormone directly, and treatment includes endocrine and metabolic monitoring.
Does preserved pulsatility mean CJC-1295 is safe?
Pulsatility describes a secretion pattern, and researchers continue to study what it means for long-term hormone balance.
Can CJC-1295 be combined with ipamorelin?
Combination protocols are popular, and because combining secretagogues can increase hormonal exposure, specialist assessment guides safe protocol design.
References
- PubMed. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
- PubMed. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
- PubMed. The Safety and Efficacy of Growth Hormone Secretagogues
Disclaimer
This information, including but not limited to texts, images, graphics, labels, ingredients, indications, potential benefits, and other materials contained on this website are for informational purposes only. No part of this website is intended to be a substitute for professional medical advice, treatment, or diagnosis. Always seek the advice of your physician or other professional healthcare provider, particularly before starting a new regimen for the first time.
Related Peptides
Wondering Whether CJC-1295 Is Right for You?
Speak with our medical team about your health goals. We will help you understand which options are supported by evidence and appropriate for your situation.